August 30, 2016 10:26 AM EDT

Neurocrine steers its ‘breakthrough’ tardive dyskinesia drug to an FDA decision

John Carroll

Editor & Founder

San Diego-based Neurocrine Biosciences announced that it has filed their NDA on a new drug for tardive dyskinesia today, but the company isn’t waiting for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Neurocrine steers its ‘breakthrough’ tardive dyskinesia drug to an FDA decision

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Bristol Myers sues the federal government over 340B, following other drugmakers

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Outlook's shares crash as wet AMD drug flunks Phase 3 test

Neu­ro­crine steers its ‘break­through’ tar­dive dysk­i­ne­sia drug to an FDA de­ci­sion

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Out­look's shares crash as wet AMD drug flunks Phase 3 test

Neurocrine steers its ‘breakthrough’ tardive dyskinesia drug to an FDA decision

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Bristol Myers sues the federal government over 340B, following other drugmakers

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Outlook's shares crash as wet AMD drug flunks Phase 3 test